Lipoprotein(a) should be taken much more seriously

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 439-441

  Kamstrup, Pia R ^a   Nordestgaard, Børge G ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; NICOTINIC ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHROMOSOME 6; CORONARY ARTERY DISEASE; EDITORIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KRINGLE DOMAIN; THROMBOSIS;

EID: 70450228759     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.57     Document Type: Editorial

References (24)

1. Berg K: A new serum type system in man - the LP system. Acta Pathol. Microbiol. Scand. 59, 369-382 (1963).
2. Utermann G: Lipoprotein(a). In: The Metabolic and Molecular Bases of Inherited Disease (2001 Edition). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGrawHill, Medical Publishing Division, NY, USA, 2753-2787 (2006).
3. Deb A, Caplice NM: Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin. Cardiol. 27(5), 258-264 (2004). (Pubitemid 38703073)
4. Boffa MB, Marcovina SM, Koschinsky ML: Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin. Biochem. 37(5), 333-343 (2004).
5. Nielsen LB, Juul K, Nordestgaard BG: Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intimainner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler. Thromb. Vasc. Biol. 18(4), 641-649 (1998). (Pubitemid 28177906)
6. Edelstein C, Pfaffinger D, Hinman J et al.: Lysinephosphatidylcholine adducts in kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein(a). J. Biol. Chem. 278(52), 52841-52847 (2003). (Pubitemid 38035883)
7. Tsimikas S, Brilakis ES, Miller ER et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353(1), 46-57 (2005). (Pubitemid 41007806)
8. Nielsen LB, Grønholdt ML, Schroeder TV, Stender S, Nordestgaard BG: In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler. Thromb. Vasc. Biol. 17(5), 905-911 (1997).
9. Alfthan G, Pekkanen J, Jauhiainen M et al.: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106(1), 9-19 (1994). (Pubitemid 24103795)
10. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270(18), 2195-2199 (1993).
11. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin. Chem. 44(11), 2301-2306 (1998).
12. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease - meta-analysis of prospective studies. Circulation 102(10), 1082-1085 (2000).
13. Erqou S, Kaptoge S, Perry PL et al.: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4), 412-423 (2009).
14. Danik JS, Rifai N, Buring JE, Ridker PM: Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296(11), 1363-1370 (2006).
15. Kamstrup PR, Benn M, TybjærgHansen A, Nordestgaard BG: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2), 176-184 (2008).
16. Kamstrup PR, TybjærgHansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22), 2331-2339 (2009).
17. Clayton D, McKeigue PM: Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 358(9290), 1356-1360 (2001). (Pubitemid 33016504)
18. Smith GD, Ebrahim S: Mendelian randomization: prospects, potentials, and limitations. Int. J. Epidemiol. 33(1), 30-42 (2004).
19. Zacho J, TybjærgHansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG: Genetically elevated Creactive protein and ischemic vascular disease. N. Engl. J. Med. 359(18), 1897-1908 (2008).
20. Holmer SR, Hengstenberg C, Kraft HG et al.: Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation. 107(5), 696-701 (2003). (Pubitemid 36222596)
21. Sandholzer C, Saha N, Kark JD et al.: Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler. Thromb. 12(10), 1214-1226 (1992).
22. Kraft HG, Lingenhel A, Kochl S et al.: Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 16(6), 713-719 (1996). (Pubitemid 26179358)
23. Kamstrup PR, TybjærgHansen A, Steffensen R, Nordestgaard BG: Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J. Clin. Endocrinol. Metab. 93(10), 3769-3776 (2008).
24. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(A) in hyperlipemic subjects treated with nicotinicacid. J. Intern. Med. 226(4), 271-276 (1989). (Pubitemid 19230908)